Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial-Reference-Cited by-同舟云学术

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

Published:2014-04-01 Issue:6 Volume:16 Page:671-677
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Jhund Pardeep S.¹²,Claggett Brian¹,Packer Milton³,Zile Michael R⁴,Voors Adriaan A.⁵,Pieske Burkert⁶,Lefkowitz Martin⁷,Shi Victor⁷,Bransford Toni⁷,McMurray John J. V.²,Solomon Scott D¹

Affiliation:

1. Cardiovascular Division; Brigham and Women's Hospital; Boston MA USA

2. BHF Glasgow Cardiovascular Research Centre; Institute of Cardiovascular and Medical Sciences, University of Glasgow; Glasgow UK

3. Department of Clinical Sciences; University of Texas Southwestern Medical Center; Dallas TX USA

4. Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina; Charleston SC USA

5. Department of Cardiology; University Medical Centre, Groningen, University of Groningen; Groningen the Netherlands

6. Department of Cardiology; Medical University Graz; Graz Austria

7. Novartis Pharmaceuticals; East Hanover NJ USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference22 articles.

1. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors;Aronow;Am J Cardiol,1997

2. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance;Setaro;American J Cardiol,1990

3. Irbesartan in patients with heart failure and preserved ejection fraction;Massie;N Engl J Med,2008

4. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial;Yusuf;Lancet,2003

5. The perindopril in elderly people with chronic heart failure (PEP-CHF) study;Cleland;Eur Heart J,2006

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A narrative review on sacubitril/valsartan and ventricular arrhythmias;Medicine;2022-07-08

2. Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies;Biomedicines;2022-03-03

3. Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?;Current Opinion in Cardiology;2021-03-09

4. Narrative review in the current role of angiotensin receptor-neprilysin inhibitors;Annals of Translational Medicine;2021-03

5. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload;ESC Heart Failure;2021-01-26